Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRANSCEND-T2D-1 (T2D monotherapy)

TRANSCEND-T2D-1 (T2D monotherapy)

Retatrutide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
t2d
Official title
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Sponsor
Eli Lilly and Company
Phase
3
Registry status
completed · 2024-04 → 2026-01
Participants
537
Duration
40 weeks
Registry
NCT06354660

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 12 mgt2d40537−16.8 % vs −2.5 %
Δ −14.3 pp
−16.8 % vs −2.5 %
Δ −14.3 pp
−1.9 vs −0.85.1 vs 0.0—————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (3)
  • retatrutide 12 mg · weight_eff · Results
    The estimated mean percent change from BL in BW was -11.5% with 4 mg, -15.5% with 9 mg, -16.8% with 12 mg retatrutide vs -2.5% with placebo (all p<0.001).
  • retatrutide 12 mg · ae_dc · Results
    Discontinuation due to AEs occurred in 2.2% (4 mg), 4.5% (9 mg), and 5.1% (12 mg) participants treated with retatrutide, versus 0% with placebo.
  • retatrutide 12 mg · hba1c · Results
    The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol/mol) with 4 mg, -2.0% (-22.0 mmol/mol) with 9 mg, and -1.9% (-21.0 mmol/mol) with 12 mg retatrutide

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRANSCEND-T2D-1 (T2D monotherapy). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.